Hosted on MSN
Mixed bag for AZN stock: AstraZeneca’s Enhertu wins FDA breakthrough, Imfinzi misses trial goal
AstraZeneca’s (AZN) breast cancer drug Enhertu has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). The FDA gave the designation based on results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback